Monjuvi: Targeted CD19 Antibody Option For Relapsed Or Refractory DLBCL

Monjuvi (tafasitamab-cxix) offers a targeted CD19-directed antibody option for adults in the US with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant, used in combination with lenalidomide under an accelerated FDA approval.

Responsible: ad hoc news Software & Services Desk. Reviewed prior to publication on June 11, 2026 at 6:08 PM ET. Details in the imprint.

Monjuvi, the brand name for tafasitamab-cxix, is a prescription CD19-directed antibody therapy used together with lenalidomide for certain adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for autologous stem cell transplant in the United States. Monjuvi provides a targeted option delivered as an intravenous infusion in 28-day cycles and is positioned as a non-transplant alternative in an aggressive blood cancer setting. The medicine is commercialized in the US through a collaboration between MorphoSys AG and Incyte.

What Monjuvi does for relapsed or refractory DLBCL patients

Monjuvi (tafasitamab-cxix) is a humanized monoclonal antibody that targets the CD19 protein on B cells, including malignant B cells involved in certain lymphomas. By binding to CD19, Monjuvi is designed to help the immune system recognize and attack cancerous B cells. This targeted action differentiates it from traditional chemotherapy, which typically affects both healthy and malignant cells.

According to the US prescribing information cited in FDA communications, Monjuvi in combination with lenalidomide is indicated for adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant. The approval was granted under the FDA's accelerated approval pathway, which allows earlier approval of drugs that treat serious conditions and fill an unmet medical need based on a surrogate endpoint.

In clinical use, Monjuvi is administered as an intravenous infusion on a defined schedule in repeated 28-day treatment cycles. During the initial treatment phase with combination therapy, dosing is more frequent, then later tapers to every two weeks, followed by Monjuvi monotherapy after lenalidomide is discontinued, as described in the US label. This infusion-based regimen means patients receive the drug in oncology or hematology care settings rather than at home.

Monjuvi is available in the US only by prescription and is typically dispensed and administered through hospital-based infusion centers, specialized oncology practices, hematology clinics, and specialty pharmacies that support complex cancer therapies. Distribution in the United States is managed under a collaboration where Incyte handles commercialization, while MorphoSys focuses primarily on antibody and oncology research and development and participates in the broader lifecycle of the product.

Within the treatment landscape for aggressive B-cell lymphomas such as DLBCL, Monjuvi plus lenalidomide represents a targeted, non-transplant option among several other therapies, including chemoimmunotherapy, CAR-T cell therapies, and other monoclonal antibodies. It is specifically positioned for adult patients whose disease has returned or not responded to previous therapies and who are not suitable candidates for an autologous stem cell transplant, a procedure that can be curative but is not feasible for all patients due to age, comorbidities, or other clinical factors.

The US label for Monjuvi includes detailed information on dosing, administration schedules, and safety considerations; physicians are advised to follow these instructions closely and monitor patients for infusion-related reactions, hematologic parameters, and other potential adverse effects as part of routine oncology practice. Monjuvi can only be used under the supervision of healthcare professionals experienced in the use of anticancer therapies.

From an access perspective, Monjuvi is distributed through specialty channels to support insurance verification, reimbursement assistance, and coordination of care given the complexity and cost of targeted oncology therapies. Patients and caregivers generally work with their treating oncologist, case managers, and specialty pharmacy partners to navigate coverage and scheduling of infusions. For many, the availability of a targeted CD19-directed antibody option adds another line of therapy in a disease that has historically been difficult to treat after relapse.

Within MorphoSys AG's portfolio, Monjuvi has been a central oncology product, reflecting the company's long-standing focus on antibody-based cancer treatments and partnerships with larger commercial organizations for market execution. MorphoSys has emphasized oncology and antibody research as a core strategic theme, and Monjuvi helps illustrate how that scientific focus translates into a marketed therapy for a clearly defined group of patients. Shares of MorphoSys AG (DE0006632003, ticker MOR) last traded on Xetra as part of the company's European listing, anchoring Monjuvi within a publicly tracked biopharmaceutical business.

Monjuvi at a glance

• Product: Monjuvi (tafasitamab-cxix)
• Manufacturer: MorphoSys AG
• Category: Software & Services - oncology therapy information
• Launch date: July 31, 2020 (US FDA accelerated approval for DLBCL indication)
• MSRP / Price: Prescription-only oncology medicine; pricing and patient cost depend on dosage, insurance coverage, and contracted rates, not publicly listed as a simple retail price.
• Availability: Prescription-only through US oncology and hematology practices, hospital infusion centers, and specialty pharmacies.
• Target audience: Adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant, as well as their treating oncology teams.
• Key feature / USP: CD19-directed monoclonal antibody used in combination with lenalidomide, offering a targeted, non-transplant option under accelerated FDA approval for a defined DLBCL patient population.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.